Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02573896
Title Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors New Approaches to Neuroblastoma Therapy Consortium
Indications

neuroblastoma

Therapies

Dinutuximab + Lenalidomide

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.